Sort   by:  
 Page size 
UnknownHighly Networked SARS-CoV-2 Peptides Elicit T Cell Responses with Enhanced Specificity.
Not available
S-EPMC10580120 | biostudies-literature
UnknownTafasitamab for patients with relapsed or refractory diffuse large B-cell lymphoma: final 5-year efficacy and safety findings in the phase II L-MIND study.
Not available
S-EPMC10828760 | biostudies-literature
UnknownPolyfunctional T peripheral helper cells are associated with the magnitude and durability of antibody responses after COVID-19.
Not available
S-EPMC12712866 | biostudies-literature
UnknownCamidanlumab tesirine for relapsed or refractory classic Hodgkin lymphoma: a phase 2 study.
Not available
S-EPMC12745010 | biostudies-literature
UnknownMulti-center analysis of practice patterns and outcomes of younger and older patients with mantle cell lymphoma in the rituximab era.
Not available
S-EPMC8511300 | biostudies-literature
UnknownOutcomes of patients with limited-stage aggressive large B-cell lymphoma with high-risk cytogenetics.
Not available
S-EPMC6988401 | biostudies-literature
UnknownOutcomes of patients with blastoid and pleomorphic variant mantle cell lymphoma.
Not available
S-EPMC10758713 | biostudies-literature
UnknownQuantifying neutralising antibody responses against SARS-CoV-2 in dried blood spots (DBS) and paired sera.
Not available
S-EPMC10495436 | biostudies-literature
Sort   by:  
 Page size